Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Generate Biomedicines, Inc.NASDAQ: GENB

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) of $1.24M in Q1 FY2026

Q1 FY2026 deferred revenue (non-current) was $1.24M.

Context

  • Deferred revenue (non-current) amounted to 0.2% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.24M— QoQ
Last fiscal yearDec 2025
$4.51M-70.3% YoY
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-70.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
4.51M USD
Year-over-year change
-70.3%
1-year CAGR
-70.3%

Deferred Revenue (Non-current) vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's Mar 2026 deferred revenue (non-current) of $1.24M is the 3rd highest of the 5 companies compared; the peer median is $24.35M.
  • Deferred revenue (non-current) amounts to 0.2% of total assets for GENB, versus a peer median of 1.8%.
GENB Competitors Peer median
Deferred Revenue (Non-current) for GENB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
STROSutro Biopharma, Inc.Mar 2026$230.34M +15.8%+35.1%95.2%
ABCLAbCellera Biologics Inc.Sep 2026$48.05M -72.5%+42.5%3.2%
GENBGenerate Biomedicines, Inc.Mar 2026$1.24M ——0.2%
ABSIAbsci CorporationMar 2026$641K ——0.3%
INBXInhibrx Biosciences, Inc.Mar 2026$0 ——0.0%
Peer median (excluding GENB) $24.35M-28.4%+38.8%1.8%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.